Medical research

Global Contract Research Organization (CRO) Markets, 2019-2020 & 2024: Increased Adoption of Hybrid Clinical Trials and Remote Patient Monitoring

Friday, September 18, 2020 - 2:30pm

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Post-Pandemic Growth Opportunity in the Global Contract Research Organization (CRO) Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Post-Pandemic Growth Opportunity in the Global Contract Research Organization (CRO) Market" report has been added to ResearchAndMarkets.com's offering.
  • With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new trials.
  • It presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market.
  • The two key market trends identified are the increased adoption of hybrid clinical trials and remote patient monitoring.

Axon Neuroscience to launch world's first crowdfunded vaccine against COVID-19

Friday, September 18, 2020 - 2:00pm

BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.

Key Points: 
  • BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.
  • With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine against COVID-19.
  • Michal Fresser, Chief Executive Officer of Axon said: "There is a global race for a vaccine.
  • The elderly can be overlooked by other vaccine developers in their push to find an effective vaccine quickly.

Axon Neuroscience to launch world's first crowdfunded vaccine against COVID-19

Friday, September 18, 2020 - 11:54am

BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.

Key Points: 
  • BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.
  • With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine against COVID-19.
  • Michal Fresser, Chief Executive Officer of Axon said: "There is a global race for a vaccine.
  • The elderly can be overlooked by other vaccine developers in their push to find an effective vaccine quickly.

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Friday, September 18, 2020 - 12:32am

Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.

Key Points: 
  • Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.
  • In a publication submitted Monday, September 14 (now available on the bioRxiv preprint server ), the authors present a systematic study on rational vaccine design and evaluation of vaccine response in mice.
  • In particular, Zhu and his team propose a new spike antigen design (S2GHR2) and displayed it on several SApNPs as COVID-19 vaccine candidates.
  • In practice, we have seen similar performance from the Merck HPV Gardasil vaccine which is essentially a protein nanoparticle vaccine.

Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?

Thursday, September 17, 2020 - 2:17pm

ET to discuss the concept of two types of immune responses antibody vs. T Cell as well as provide an overview of the challenges of developing an effective vaccine.

Key Points: 
  • ET to discuss the concept of two types of immune responses antibody vs. T Cell as well as provide an overview of the challenges of developing an effective vaccine.
  • Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
  • Tonixs lead vaccine candidate, TNX-1800*, is a live replicating, attenuated vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response.
  • Tonix is also developing TNX-2300* and TNX-2600*, live replicating vaccine candidates for the prevention of COVID-19, but using bovine parainfluenza as the vector.

Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day

Thursday, September 17, 2020 - 11:59am

The Moderna team has made significant progress since our last R&D Day 12 months ago.

Key Points: 
  • The Moderna team has made significant progress since our last R&D Day 12 months ago.
  • Across Modernas pipeline, more than 27,000 healthy volunteers and patients have been enrolled in clinical studies including the Phase 3 study of mRNA-1273.
  • The Companys global public health portfolio is focused on epidemic and pandemic diseases for which funding has been sought from governments and non-profit organizations.
  • The most common solicited systemic ARs were headache, fatigue, and myalgia in both CMV-seronegative and CMV-seropositive mRNA-1647 treatment groups.

BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021

Thursday, September 17, 2020 - 9:00am

The manufacturing site will expand BioNTechs COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month, once fully operational.

Key Points: 
  • The manufacturing site will expand BioNTechs COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month, once fully operational.
  • The Marburg production site is a state-of-the-art, multi-platform GMP certified manufacturing facility that currently employs approximately 300 people.
  • This acquisition reflects BioNTechs commitment to significantly expanding its manufacturing capacity in order to supply a potential vaccine worldwide upon authorization or approval.
  • The acquisition will accelerate BioNTechs efforts to scale-up its commercial manufacturing capacity to produce its mRNA COVID-19 vaccine candidate BNT162.

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

Wednesday, September 16, 2020 - 9:01pm

Chiesi Group will lead development and worldwide commercialization activities and will fund all expenses related to the collaboration.

Key Points: 
  • Chiesi Group will lead development and worldwide commercialization activities and will fund all expenses related to the collaboration.
  • We are excited to begin this collaboration with Chiesi Group, which provides the opportunity to further leverage our mRNA and delivery technology, said Stephen Hoge, M.D., President of Moderna.
  • Chiesi Group is at the forefront of innovation and discovery of novel therapies for people affected by diseases with high unmet medical need, said Ugo Di Francesco, Chief Executive Officer of Chiesi Group.
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Catalent Biologics and Humanigen to Present a Case Study on Accelerated Scale Up of a Monoclonal Antibody to Treat COVID-19 at BioProcess International Conference

Wednesday, September 16, 2020 - 7:25pm

The COVID-19 pandemic has seen innovators looking to accelerate timelines in order to bring safe and effective potential therapies to patients quickly.

Key Points: 
  • The COVID-19 pandemic has seen innovators looking to accelerate timelines in order to bring safe and effective potential therapies to patients quickly.
  • A Phase 3 study is currently underway evaluating hospitalized patients with COVID-19.
  • She has managed a variety of clinical, process and performance qualification, and commercial projects, supporting drug substance manufacturing, drug product filing, and packaging.
  • Dr. Durrant is an entrepreneur, board member, C-level executive, former big pharma executive and a medical doctor by original training.

Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials

Wednesday, September 16, 2020 - 5:26pm

Our team is grateful for the tireless efforts of the many scientists and clinicians that have made it possible to achieve this milestone so quickly.

Key Points: 
  • Our team is grateful for the tireless efforts of the many scientists and clinicians that have made it possible to achieve this milestone so quickly.
  • LY-CoV555 is developed from an antibody that was identified from the blood of a recovered COVID-19 patient using AbCelleras pandemic response platform.
  • LY-CoV555 was selected as the lead candidate from this group of antibodies, and is the worlds first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials.
  • LY-CoV555 emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.